LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001
LEXEO Therapeutics, a clinical-stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX1001, the company’s adeno-associated virus (AAV) mediated gene therapy program, for the potential treatment of apolipoprotein E4 (APOE4) associated Alzheimer’s disease. LX1001 is a CNS-administered therapy being evaluated in an ongoing Phase 1 clinical trial.
LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease
Initial Phase 1 clinical data expected in 2H 2021